ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 906.7 USD | -0.84% |
|
+1.86% | +55.55% |
| 07-02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| 07-02 | Eli Lilly Gets FDA Approval for Alzheimer's Disease Drug | MT |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.55% | 823B | |
| +42.31% | 641B | |
| -6.83% | 352B | |
| +17.15% | 324B | |
| +7.09% | 301B | |
| +14.02% | 241B | |
| +1.64% | 223B | |
| +13.66% | 218B | |
| +7.87% | 167B | |
| -3.33% | 160B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Nektar Therapeutics Sues Eli Lilly in California Over Autoimmune Disease Therapy Claims
